Holen Sie sich die Stockscreener-App
2.07
0.96%
-0.02
Vorhandelsmarkt:
2.11
0.04
+1.93%
Schlusskurs vom Vortag:
$2.09
Offen:
$2.095
24-Stunden-Volumen:
6.51M
Relative Volume:
0.95
Marktkapitalisierung:
$2.24B
Einnahmen:
$1.31M
Nettoeinkommen (Verlust:
$-597.65M
KGV:
-2.134
EPS:
-0.97
Netto-Cashflow:
$-425.62M
1W Leistung:
-18.50%
1M Leistung:
-20.38%
6M Leistung:
-62.84%
1J Leistung:
-74.32%
1-Tages-Spanne:
$2.03
$2.2099
1-Wochen-Bereich:
$1.83
$2.425
52-Wochen-Spanne:
$1.83
$9.16
Immunitybio Inc Stock (IBRX) Company Profile
Firmenname
Immunitybio Inc
Sektor
Branche
Telefon
(844) 696-5235
Adresse
3530 JOHN HOPKINS COURT, SAN DIEGO
Vergleichen Sie IBRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.07 | 2.24B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-10 | Eingeleitet | BTIG Research | Buy |
| 2023-05-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | Eingeleitet | Jefferies | Buy |
Immunitybio Inc Aktie (IBRX) Neueste Nachrichten
Is ImmunityBio, Inc. (IBRX) the Low Risk High Reward Stock Set to Triple by 2030? - Yahoo Finance
10 Low Risk High Reward Stocks Set to Triple by 2030 - Insider Monkey
‘Arbitrary’ FDA decision-making puts U.S. innovation at risk, says Soon-Shiong - biocentury.com
ImmunityBio (IBRX) Faces FDA Setback in Bladder Cancer Therapy A - GuruFocus
ImmunityBio Stock Tumbles 18% After FDA Issues Refuse To File Letter: But Retail’s Positive By Stocktwits - Investing.com India
ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio Stock Tumbles 18% After FDA Issues Refuse To File Letter: But Retail’s Positive - MSN
ImmunityBio (IBRX) Faces Filing Setback with FDA's Unanticipated Response | IBRX Stock News - GuruFocus
CG Oncology Jumps 25% on Positive Trial Results - Orange County Business Journal
Unity lays off ‘all’ workers; Novo to get FDA decision on oral Wegovy this year - Endpoints News
ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug - Benzinga
ImmunityBio stock sinks after FDA issues RTF letter By Investing.com - Investing.com Nigeria
ImmunityBio stock sinks after FDA issues RTF letter - Investing.com Australia
ImmunityBio (IBRX) Faces Setback with FDA Refusal for Cancer Tre - GuruFocus
ImmunityBio Seeks Urgent FDA Meeting After Rejection for Bladder Cancer Therapy - marketscreener.com
ImmunityBio Requests An Urgent Meeting With FDA To Address The Change In The Agency'S Unambiguous Guidance On Jan 2025 To Submit A SBLA For NMIBC BCG Unresponsive Papillary Disease, Following An Inconsistent Refusal To File Letter On May - marketscreener.com
ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency’s Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 20 - Business Wire
ImmunityBio (IBRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
ImmunityBio Announces Oral Presentation of Phase 2/3 Clinical Trial Results of Patients with BCG-Unresponsive Bladder Cancer Carcinoma at the Upcoming American Urological Association’s Annual Meeting - The Globe and Mail
Wainwright maintains $8 target on ImmunityBio shares post-AUA By Investing.com - Investing.com India
Wainwright maintains $8 target on ImmunityBio shares post-AUA - Investing.com
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of ImmunityBio, Inc.(IBRX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
IBRX LAWSUIT ALERT: Levi & Korsinsky Notifies ImmunityBio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio's Bladder Cancer Treatment Shows High Cystectomy Avoidance, Long-Term Response - marketscreener.com
IBRX Study Reveals Promising Results for Non-Muscle Invasive Bla - GuruFocus
Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up - marketscreener.com
Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best i - StreetInsider
SHAREHOLDER ALERT: Potential Recovery for ImmunityBio, Inc. (IBRX) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Dr Dinney on the Association Between UGDB and Cretostimogene Grenadenorepvec Response in NMIBC - OncLive
ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting - BioSpace
Why ImmunityBio, Inc. (IBRX) Declined on Wednesday - Insider Monkey
Economic Uncertainties Batter Trading in These 10 Firms - Insider Monkey
ImmunityBio sees Q1 sales surge, submits FDA applications By Investing.com - Investing.com South Africa
ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia - BioSpace
ImmunityBio Completes FDA License Application Submissions - marketscreener.com
Immunitybio Announces FDA Submissions Of Supplemental BLA For Nmibc Papillary Disease And For Expanded Access Of Anktiva®To Treat Lymphopenia - marketscreener.com
ImmunityBio sees Q1 sales surge, submits FDA applications - Investing.com
Why ImmunityBio Inc. (IBRX) Skyrocketed On Monday? - MSN
Is ImmunityBio Stock Heading Upwards? - timothysykes.com
ImmunityBio raises $75 million in direct offering - The Pharma Letter
ImmunityBio settles securities class action lawsuit for $10.5 million - Claim Depot
ImmunityBio, Inc. (IBRX): Among Stocks Under $10 that Will Triple - Insider Monkey
Finanzdaten der Immunitybio Inc-Aktie (IBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.84%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):